Investor AB stock: Atlas Antibodies appoints interim CEO Henneveld

Investor AB's portfolio company Atlas Antibodies has appointed Morten Henneveld as interim chief executive, according to an Investor AB press release published on Monday, November 2, 2026. The appointment took effect on Sunday, November 1, after Dan Pitulia left the role by mutual agreement with the board.

Atlas Antibodies changes leadership

Henneveld most recently served as chief executive of OssDsign and previously held leadership positions at GN Group, Zimmer Biomet and Coloplast. Atlas Antibodies chair Åsa Riisberg said his leadership experience and record in strategic change would support the company's continued development.

Thomas Kidane, co-head of Patricia Industries, welcomed Henneveld and thanked Pitulia for his contribution. The announcement concerns an operating company in Investor AB's portfolio, not a change to Investor AB's own executive leadership.

For shareholders, the appointment adds a portfolio-company transition to Investor AB's active-ownership agenda. The practical significance will depend on execution under the interim leadership and on the process for the next phase of development. The press release does not set financial targets or a timetable for a permanent appointment.

Investor AB stock at Lang & Schwarz

Investor AB stock traded at 38.94 euros on Lang & Schwarz at 15:33 CET on Monday, November 2, 2026. The real-time quote of Investor AB stock is available for ongoing monitoring.

Swedish equities are covered in the OMXS30 market environment.

Further developments can be followed through more news and analyses on Investor AB stock.